Dcf Advisers, LLC Aptinyx Inc. Transaction History

Dcf Advisers, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.38 - $2.58 $3,218 - $21,855	-8,471 Reduced 14.86%	48,529 $27,000
Q4 2021 Feb 10, 2022	SELL	$2.11 - $3.0 $120,270 - $171,000	-57,000 Reduced 50.0%	57,000 $152,000
Q2 2021 Aug 13, 2021	SELL	$2.39 - $3.5 $38,240 - $56,000	-16,000 Reduced 12.31%	114,000 $323,000
Q1 2021 May 12, 2021	SELL	$2.86 - $4.33 $2,860 - $4,330	-1,000 Reduced 0.76%	130,000 $390,000
Q4 2020 Feb 12, 2021	BUY	$2.93 - $4.3 $114,856 - $168,560	39,200 Added 42.7%	131,000 $453,000
Q3 2020 Nov 13, 2020	SELL	$3.05 - $4.99 $45,750 - $74,850	-15,000 Reduced 14.04%	91,800 $310,000
Q2 2020 Aug 13, 2020	BUY	$1.99 - $4.4 $1,990 - $4,400	1,000 Added 0.95%	106,800 $445,000
Q1 2020 May 12, 2020	BUY	$1.81 - $5.03 $26,245 - $72,935	14,500 Added 15.88%	105,800 $229,000
Q4 2019 Feb 12, 2020	BUY	$2.84 - $4.25 $259,292 - $388,025	91,300 New	91,300 $312,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.